G01N33/56983

Antibody therapies and methods for treating coronavirus infection

Described herein are methods of treating COVID19 from a coronavirus infection, methods of treating a subject having a coronavirus infection, methods of improving a survival rate of a subject having a coronavirus infection, methods of determining prognosis of a subject having a coronavirus infection, methods of preventing or treating organ-dysfunction or multi-organ dysfunction or failure associated with a coronavirus infection, methods of combinational therapy for a subject having a coronavirus infection, methods of reducing microthrombi formation or low flow organ-ischemia associated with a coronavirus infection by administering a DEspR inhibitor.

METHOD AND COMPOSITION FOR DETERMINING SPECIFIC ANTIBODY RESPONSES TO SPECIES OF FILOVIRUS
20230050394 · 2023-02-16 ·

The disclosure relates to compositions, assays, methods and kits comprising one or more amino acid sequences of a filovirus protein, or a fragment thereof, which find use in the detection of a filovirus infection and/or the presence of antibodies specific for a filovirus in a biological sample.

ANTIBODY STAIN WITH LOW FLUOROPHORE RATIO FOR STAINING VIRUS-SIZE PARTICLES

A method for evaluating a biological material for unassociated virus-size particles having a particular epitope uses a fluorescent antibody stain specific for binding with the epitope and a fluid sample with the virus-size particles and fluorescent antibody stain is subjected to flow cytometry with identification of fluorescent emission detection events indicative of passage through a flow cell of a flow cytometer of unassociated labeled particles of virus size including such a virus-size particle and fluorescent antibody stain.

RNA DETERMINANTS FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS

Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of a determinant which is set forth in Tables 1 or 2 in a sample derived from the subject, wherein said amount is indicative of the infection type.

Chimeric insect-specific flaviviruses

Chimeric proteins that comprise one or more amino acid sequences of an insect-specific flavivirus and one or more other immunogenic proteins are provided. The chimeric proteins are suitably capable of forming virus particles. The chimeric protein and/or virus particle may be suitable for delivery to a subject to elicit an immune response to a pathogen and/or for diagnosis or detection of a pathogen. Also provided are nucleic acids and vectors encoding the chimeric proteins, and isolated chimeric insect-specific flaviviruses comprising the chimeric proteins and/or nucleic acids.

NANOMATERIALS COATED WITH CALIXARENES

This invention concerns a versatile and simple one-pot method to prepare nanomaterials, and in particular nanoparticles, grafted with an ultra-thin layer of calixarenes by placing at 5 least one oxidized metal with at least one calix[n]arene diazonium salt in the presence of a reducing agent in a solvent, and heating the traction mixture to obtain a metal-based nanomaterial coated with calix[n]arenes. The invention further concerns the coupling of organic molecules or biomolecules to the calixarene-grafted nanomaterials in order to further functionalize the surface of the particles. The metal-based nanomaterial coated with 10 calix[n]arenes can for example be used in immunoassays.

Rapid verification of virus particle production for a personalized vaccine

Methods for rapidly confirming production of infectious viral vectors, for use in clinical grade personalized neo-antigen vaccines for subjects in need thereof, are provided.

METHODS OF DIAGNOSING AND CLASSIFYING VIRAL INFECTIONS

A method of classifying the severity of a coronaviral infection of a subject is disclosed. The method comprises measuring the TRAIL and/or IP10 protein level in a body liquid sample of the subject, wherein the level is indicative of the severity of the coronaviral infection. Managing treatments for coronaviral infections are also disclosed as well as measuring contagiousness of infections.

PROTEIN-BASED PURIFICATION MATRICES AND METHODS OF USING THE SAME
20230099707 · 2023-03-30 ·

Provided herein are protein-based purification matrices and methods of use thereof to purify biologics and/or to remove contaminants from a composition. Methods of bringing two or more biologics in close proximity are also provided. The disclosed compositions and methods allow for faster, more efficient purification of a biologic compared to traditional affinity chromatography.

Method for efficiently inducing antibody, antibody and detection system for hepatitis virus

An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.